IMR Stock Overview
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AC Immune SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.07 |
| 52 Week High | US$4.73 |
| 52 Week Low | US$2.06 |
| Beta | 1.28 |
| 11 Month Change | 10.45% |
| 3 Month Change | 9.46% |
| 1 Year Change | 12.07% |
| 33 Year Change | -32.19% |
| 5 Year Change | -59.54% |
| Change since IPO | -78.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| IMR | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.3% | -0.7% | -0.02% |
| 1Y | 12.1% | -17.2% | 8.2% |
Return vs Industry: IMR exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: IMR exceeded the German Market which returned 8.2% over the past year.
Price Volatility
| IMR volatility | |
|---|---|
| IMR Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: IMR's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: IMR's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 147 | Andrea Pfeifer | www.acimmune.com |
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company’s SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It is developing Crenezumab, a humanized, conformation-specific monoclonal antibody used to slow Alzheimer’s disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD.
AC Immune SA Fundamentals Summary
| IMR fundamental statistics | |
|---|---|
| Market cap | €321.14m |
| Earnings (TTM) | -€42.81m |
| Revenue (TTM) | €44.00m |
7.3x
P/S Ratio-7.5x
P/E RatioIs IMR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMR income statement (TTM) | |
|---|---|
| Revenue | CHF 40.97m |
| Cost of Revenue | CHF 61.43m |
| Gross Profit | -CHF 20.46m |
| Other Expenses | CHF 19.41m |
| Earnings | -CHF 39.86m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | -49.93% |
| Net Profit Margin | -97.29% |
| Debt/Equity Ratio | 0% |
How did IMR perform over the long term?
See historical performance and comparison